WO2026138966 - ADENO-ASSOCIATED VIRUS CAPSID PROTEIN MUTANT AND ADENO-ASSOCIATED VIRUS
National phase entry is expected:
Publication Number
WO/2026/138966
Publication Date
02.07.2026
International Application No.
PCT/CN2025/145621
International Filing Date
25.12.2025
Title **
[English]
ADENO-ASSOCIATED VIRUS CAPSID PROTEIN MUTANT AND ADENO-ASSOCIATED VIRUS
[French]
PROTÉINE DE CAPSIDE DE VIRUS ADÉNO-ASSOCIÉ MUTANTE ET VIRUS ADÉNO-ASSOCIÉ
[Chinese]
一种腺相关病毒衣壳蛋白突变体及腺相关病毒
Applicants **
CHENGDU ORIGEN BIOTECHNOLOGY CO., LTD.
Inventors
LUO, Shuang
ZHENG, Qiang
KE, Xiao
Priority Data
202411928292.5
25.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2185 | |
| EPO | Filing, Examination, Granting | 19453 | |
| Japan | Filing, Examination, Granting | 2690 | |
| South Korea | Filing, Examination, Granting | 3248 | |
| USA | Filing, Examination, Granting | 6740 |
Total:
34,316
Contact Us
Abstract[English]
Provided are a modified adeno-associated virus capsid protein and the use thereof. The capsid protein comprises a substitution of about 5-8 amino acids as compared with a wild-type AAV capsid protein, and an AAV comprising the mutated capsid protein has increased infectivity to target tissue or target cells (such as heart or cardiomyocytes) than an AAV comprising the unmutated wild-type AAV capsid protein.[French]
L'invention concerne une protéine de capside de virus adéno-associé modifiée et son utilisation. La protéine de capside comprend une substitution d'environ 5 à 8 acides aminés par rapport à une protéine de capside d'AAV de type sauvage, et un AAV comprenant la protéine de capside mutée présentant une infectivité accrue pour un tissu cible ou des cellules cibles (tels que le cœur ou les cardiomyocytes) par rapport à un AAV comprenant la protéine de capside d'AAV de type sauvage non mutée.[Chinese]
提供一种经过修饰的腺相关病毒衣壳蛋白及其用途，所述衣壳蛋白相对于野生型AAV衣壳蛋白包含约5-8个氨基酸的取代，并且包含所述经过突变的衣壳蛋白的AAV与包含未突变的野生型AAV衣壳蛋白的AAV相比，对靶组织或靶细胞(例如心脏或心肌细胞)具有增加的感染性。